Sponsor intelligence · OTHER
Clinical trials sponsored by
Tianjin Medical University Cancer Institute And Hospital.
Real, source-linked trial activity for Tianjin Medical University Cancer Institute And Hospital: 2 tracked trials, by phase and status, newest first. New trials = pipeline expansion = CRO, site, and reagent demand.
✔ Verified against the public NIH RePORTER & ClinicalTrials.gov records as of Jun 21, 2026. Source-linked, daily-refreshed.
PHASE2 2
Newest Tianjin Medical University Cancer Institute And Hospital trials
| Posted | Trial | Phase | Status | |
|---|---|---|---|---|
| 3d ago | Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI | Ph 2 | ACTIVE_NOT_RECRUITING | ↗ |
| 4d ago | Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therap | Ph 2 | ACTIVE_NOT_RECRUITING | ↗ |
Get this lane pushed to you the day a new grant or trial lands
Free email digest + a daily new-funding feed (JSON / MCP / webhook) of newly-awarded NIH grants and newly-registered clinical trials for Tianjin Medical University Cancer Institute And Hospital (trial sponsor). Watch institutions, PIs, sponsors, and topics. Newly-funded labs = new buyers, today.